4588

Oncolys BioPharma Inc.

オンコリスバイオファーマ株式会社
Healthcare · Biotechnology
Oncolys BioPharma Inc. engages in the research, development, manufacturing, sale, and import of oncolytic viruses, drugs and medicines, and tumor diagnostic agents in Japan, the United States, and Asia. Its product pipeline comprises Telomelysin (OBP-301), an oncolytic viral immunotherapy which is in phase II clinical trial to treat gastric cancer; phase I clinical trial for the treatment of HCC; and treatment of esophageal cancer. The company also develops OBP-601(Censavudine), which is in phase II clinical trial to treat progressive supranuclear palsy, amyotrophic lateral sclerosis, and aicardi-goutieres syndrome; OBP-702, which is in preclinical trial to treat pancreatic cancer; OBP-201, which is in preclinical trial to treat viral infections; OBP-702 for the treatment of ophthalmology which is in preclinical trial. In addition, it develops TelomeScan (OBP-401 and OBP-1101), which is in pilot study trial to treat cancer testing. The company was incorporated in 2004 and is headquartered in Minato, Japan.
← Companies
Price
¥2,765
Market Cap
¥81.0B
Ent. Value
¥77.6B
Net Cash
¥3.4B
Shares Out.
29.3M
P / E
—
EV / EBIT
—
P / Book
20.27×
P / NCAV
20.56×
Div. Yield
—
Financials
Metric FY 2025
EDINET ↗ 		FY 2024
EDINET ↗ 		FY 2023
EDINET ↗ 		FY 2022
EDINET ↗ 		FY 2021
EDINET ↗
Net Sales ¥29M ¥31M ¥63M ¥976M ¥642M
Gross Profit ¥29M ¥31M ¥31M ¥338M ¥199M
SG&A ¥2.1B ¥1.7B ¥2.0B ¥1.5B ¥1.7B
Operating Income ¥-2.0B ¥-1.7B ¥-1.9B ¥-1.2B ¥-1.5B
Non-Operating Income ¥4M ¥46M ¥32M ¥63M ¥39M
Dividend Income ¥0M ¥0M ¥0M ¥0M ¥0M
Interest Income ¥4M ¥2M ¥1M ¥1M ¥0M
Non-Operating Expenses ¥31M ¥28M ¥16M ¥22M ¥85M
Interest Expense ¥5M ¥5M ¥4M ¥4M ¥4M
Ordinary Income ¥-2.1B ¥-1.7B ¥-1.9B ¥-1.2B ¥-1.5B
Pre-tax Income ¥-2.1B ¥-1.7B ¥-1.9B ¥-1.1B ¥-1.6B
Income Taxes ¥4M ¥4M ¥3M ¥3M ¥4M
Current Tax ¥4M ¥4M ¥3M ¥3M ¥4M
Net Income (owners) ¥-2.1B ¥-1.7B ¥-1.9B ¥-1.1B ¥-1.6B
EBITDA ¥-2.0B ¥-1.7B ¥-1.9B ¥-1.2B ¥-1.4B
EPS ¥-80.00 ¥-77.17 ¥-108.92 ¥-66.31 ¥-95.50
Shares Outstanding 29.3M 25.0M 19.7M 17.4M 17.4M
Shares Issued (total) 29.3M 25.0M 19.7M 17.4M 17.4M